Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

369 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-01

Study Completion Date

2025-04-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitamin D is hypothesized to play a role in the immunopathology and progression of multiple sclerosis (MS), yet its association with neurological disability remains uncertain, particularly in North African populations.We conducted a cross-sectional study involving 369 adult MS patients across two tertiary neurology centers in Western Libya. Serum 25-hydroxyvitamin D \[25(OH)D\] levels and Expanded Disability Status Scale (EDSS) scores were collected. Pearson correlation, ANOVA, and multivariable linear regression were used to assess associations between vitamin D and disability, adjusting for age, BMI, disease duration, and physical activity. Missing data and outliers were handled systematically using validated R and Python workflows.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D3 and the Stress-axis in MS

NCT02096133

Multiple Sclerosis

TERMINATED PHASE2

Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients

NCT01952483

Multiple Sclerosis (MS)

COMPLETED

Vitamine D in Multiple Sclerosis

NCT01768039

Multiple Sclerosis

UNKNOWN PHASE3

Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis

NCT01753375

Multiple Sclerosis

UNKNOWN PHASE2

Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients

NCT03610139

Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Clinically Isolated Syndrome +2 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Libyan nationals.
* aged 18 years or older.
* diagnosis of MS based on the 2017 revised McDonald criteria.
* capable of providing informed consent.
* had complete clinical, demographic, and biochemical data.

Exclusion Criteria

* presence of other neurological disorders that could mimic MS (e.g., neuromyelitis optica spectrum disorder or Lyme disease).
* missing or incomplete medical records.
* pregnancy or lactation.
* extreme psychiatric or cognitive impairment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No